Genomic Medicine · global
From Protein Supplementation to Gene Correction: Early Evidence from Human Trials for AAT Deficiency
Seven patients have received an experimental base-editing treatment, and a liver biopsy from one showed that more than half of the alleles tested had been corrected. This provides human evidence for addressing the genetic root of the disease, but whether it can protect the lungs and liver over the long term remains a question for larger trials.
For some patients with severe alpha-1 antitrypsin deficiency, weekly protein infusions are an important treatment for maintaining lung protection. Researchers are now trying to restore the liver’s ability to produce functional protein. Early human results announced by teams in Germany and China offer evidence for directly correcting the disease-causing gene, shifting the treatment focus from replacing the missing protein toward addressing the root of the disease.
The German Center for Lung Research (DZL) said on November 3 that seven patients had received base-editing treatment through a collaboration between Hannover Medical School and Shanghai Renji Hospital. However, this progress must be considered separately from the published evidence: the paper in the Journal of Hepatology described by the Alpha-1 Foundation the following day focuses on liver biopsy results from one 66-year-old man, rather than a complete efficacy and safety analysis of all seven patients.
The patient has the PI*ZZ genotype and is participating in the YOLT-202 Phase I/Ia trial. In patients with this genotype, a SERPINA1 gene variant causes abnormal alpha-1 antitrypsin (AAT) to accumulate in the liver while reducing the amount of protective AAT in the blood. This can damage the liver and leave the lungs more vulnerable to damage from enzymes in the body, gradually leading to emphysema. The idea behind gene correction is to put protein production back on track.
Base editing targets a single letter in DNA. According to DZL, the research team uses CRISPR-associated tools to change the mutated base, then makes a single-strand nick to guide the cell in repairing the other DNA strand, without using a double-strand DNA break. This strategy directly addresses the existing mutation and differs from adding a normal copy of a gene to cells.
The most direct evidence comes from liver tissue obtained ten weeks after treatment. Citing the paper, the foundation reported that analyses using Sanger and Illumina sequencing found that 54% and 57% of the alleles tested, respectively, had been corrected. These figures describe the proportion of gene correction in the tissue sample and cannot be directly translated into how much health the patient has regained. Follow-up blood tests showed that circulating AAT persisted and retained its biological activity in inhibiting elastase.
The safety findings also need to be interpreted in the context of an early study. The man experienced a transient rise in transaminases, which subsequently returned to baseline; the biopsy showed no liver inflammation, and testing detected no unintended bystander editing or off-target signals. However, a single case and the current scope of testing remain insufficient to rule out rare or delayed risks. Nor has the treatment been shown to reduce long-term clinical risks such as declining lung function or cirrhosis.
DZL said the team plans to continue clinical research in Hannover in early 2027, and the therapy has not yet been approved for marketing. Even if the liver can resume producing functional AAT, this does not establish that existing lung and liver damage has been reversed. The key questions for the next stage are whether more patients can achieve consistent and lasting improvements in the protein, and whether these molecular changes can ultimately translate into protection of organ function.